Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Wharton's jelly-derived mesenchymal stem cells (BioXcellerator)
- Development stage
- Unknown
- Lead developer
- BioXcellerator
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
BioXcellerator's Wharton's jelly-derived mesenchymal stem cells (WJ-MSCs) are an allogeneic cell therapy investigated for the treatment of severe COVID-19-related acute respiratory distress syndrome (ARDS). These stem cells are harvested from the umbilical cord's Wharton's jelly, a gelatinous substance surrounding the umbilical blood vessels. The therapy is designed to counteract pulmonary damage induced by SARS-CoV-2 through potent immunomodulatory effects, which help manage the systemic inflammation and 'cytokine storm' often seen in critically ill patients. Additionally, WJ-MSCs exhibit pro-angiogenic properties and provide protection to lung epithelial cells, potentially accelerating recovery and improving clinical outcomes. BioXcellerator initiated a Phase 1/2 randomized controlled trial in Colombia, with regulatory approval from INVIMA, to evaluate the safety and efficacy of intravenous infusions of these cells in combination with standard care.
- Other names
- Wharton's jelly derived Mesenchymal stem cellsWJ-MSC
Beyond the preview
Go deeper on Wharton's jelly-derived mesenchymal stem cells (BioXcellerator).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Wharton's jelly-derived mesenchymal stem cells (BioXcellerator).